<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Certolizumab pegol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08904</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Certolizumab pegol is a recombinant Fab&#8217; antibody fragment against tumor necrosis factor alpha which is conjugated to an approximately 40kDa polyethylene glycol (PEG2MAL40K). Polyethylene glycol helps to delay the metabolism and elimination of the drugs. Chemically, the light chain is made up of 214 amino acid residues while the heavy chain is composed of 229 amino acid residues. The molecular mass of the Fab&#8217; antibody fragment itself is 47.8 kDa. It is used for the treatment of rheumatoid arthritis and Crohn&#8217;s disease. <span class="caps">FDA</span> approved on April 22, 2008</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>2115</sub>H<sub>3252</sub>N<sub>556</sub>O<sub>673</sub>S<sub>16</sub> </td></tr><tr><th>Protein average weight</th><td>91 kDa </td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;Amino acid sequence of the light chain
DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPY
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</pre><pre class="sequence">&gt;Amino acid sequence of the heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIY
ADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB08904/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>CDP870</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cimzia </td><td>UCB, Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/tnf-inhibitor">TNF inhibitor</a></li></ul></td></tr><tr><th>CAS number</th><td>428863-50-7</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA). </td></tr><tr><th>Pharmacodynamics</th><td>TNF&#945; is a key pro-inflammatory cytokine with a central role in inflammatory processes. Biological activity associated to TNF&#945; include the upregulation of cellular adhesion molecules and chemokines, upregulation of major histocompatibility complex (MHC) class I and class II molecules, and direct leukocyte activation. TNF&#945; stimulates the production of downstream inflammatory mediators, including interleukin-1, prostaglandins, platelet activating factor, and nitric oxide. After treatment with certolizumab pegol, patients with Crohn's disease demonstrated a decrease in the levels of C-reactive protein (CRP). </td></tr><tr><th>Mechanism of action</th><td>Certolizumab pegol binds to free and membrane-bound human TNF&#945; with a KD of 90pM and neutralizes its activity. Extent of neutralization is also dose-dependent. It also inhibited the release of lipopolysaccharide-induced IL-1&#946; from monocytes. TNF&#945; is a key pro-inflammatory cytokine with a central role in inflammatory processes in which elevated levels have been observed in patients with RA and Crohn's. Certolizumab pegol selectively neutralizes TNF&#945; (IC90 of 4 ng/mL for inhibition of human TNF&#945; in the in vitro L929 murine fibrosarcoma cytotoxicity assay). It does not bind to TNF-&#946;. As certolizumab is only a Fab' fragment and thus missing the Fc region, it does not fix complement or cause antibody-dependent cell-mediated cytotoxicity. Furthermore, apoptosis of monocytes or lymphocytes, or neutrophil degranulation have not been observed in vitro. </td></tr><tr><th>Absorption</th><td>There is a linear relationship between dose administered and Cmax and AUC. A mean Cmax of approximately 43 to 49 mcg/mL occurred at Week 5 during the initial loading dose period using the recommended dose regimen for the treatment of patients with rheumatoid arthritis (400 mg sc at Weeks 0, 2 and 4 followed by 200 mg every other week).
Tmax, SubQ dose = 54 - 171 hours;
Bioavailability, SubQ dose = 80% (range of 76% - 88%) </td></tr><tr><th>Volume of distribution</th><td><p>Vd, steady state, Crohn&#8217;s and RA patients = 6 &#8211; 8 L</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism has not been studied in humans. </p></td></tr><tr><th>Route of elimination</th><td>The route of elimination of certolizumab pegol has not been studied in human subjects. Studies in animals indicate that the major route of elimination of the PEG component is via urinary excretion.</td></tr><tr><th>Half life</th><td>Terminal plasma elimation half-life = 14 days (for all doses); </td></tr><tr><th>Clearance</th><td><p>IV dose, healthy subjects = 9.21 mL/h to 14.38 mL/h;<br>
SC dose, Crohn&#8217;s disease patients = 17 mL/h;<br>
SC dose, RA patients = 21.0 mL/h;</p></td></tr><tr><th>Toxicity</th><td>The most common adverse reactions (incidence &#8805;7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection</td><td>Subcutaneous</td><td>200 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>Canada</td><td>2380298</td><td>2010-09-28</td><td>2021-06-05</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li><span class="caps">FDA</span> label</li>
	<li>Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R: Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/<span class="caps">DDDT</span>.S31658. Print 2013. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23620660">Pubmed</a></li>
	<li>Ferrante M, Vermeire S, Rutgeerts P: Certolizumab pegol in the treatment of Crohn&#8217;s disease. Expert Opin Biol Ther. 2013 Apr;13(4):595-605. doi: 10.1517/14712598.2013.777039. Epub 2013 Mar 4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23451881">Pubmed</a></li>
	<li>https://data.epo.org/publication-server/rest/v1.0/publication-dates/20110803/patents/EP1534753NWB1/document.html</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA165107055" target="_blank">PA165107055 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cimzia-drug.htm" target="_blank">http://www.rxlist.com/cimzia-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/ppa/certolizumab-pegol.html" target="_blank">http://www.drugs.com/ppa/certolizumab-pegol.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Certolizumab_pegol" target="_blank">Certolizumab_pegol <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L04AB05<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L04#L04">L04 &#8212; IMMUNOSUPPRESSANTS</a></li><li><a href="/atc/L04A#L04A">L04A &#8212; IMMUNOSUPPRESSANTS</a></li><li><a href="/atc/L04AB#L04AB">L04AB &#8212; Tumor necrosis factor alpha (TNF-?) inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>56:92</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08904.pdf?1370986451">show</a>(595 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08904.pdf?1370986451">show</a>(479 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01281">Abatacept</a></td><td>Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB00026">Anakinra</a></td><td>Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB06674">golimumab</a></td><td>Avoid combination due to the potential increased immunosuppression of Certolizumab Pegol.</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB00073">Rituximab</a></td><td>Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>